| Name | Title | Contact Details |
|---|---|---|
Terri Fleener |
Director Talent Acquisition | Profile |
James Wilkerson |
Vice President, Marketing | Profile |
Melissa Bren |
Associate Director, Client Care | Profile |
David Vogel |
Vice President, Digital Marketing and Marketing Operations | Profile |
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Talley Group | Specialists in pressure relieving mattresses and cushions, electric bed frames, negative pressure wound therapy, IPC, and infection control
Aortic solutions that address every segment of the aorta. #borntostandout